| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6636b59c3149a23a6ae7feaa3984d05f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-07049
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 |
| filingDate |
2018-01-23^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8ca4a23781aa695ec77a98bbec5c1aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5874394872d836a867e74f0bdbd0ad8f |
| publicationDate |
2019-11-05^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110418840-A |
| titleOfInvention |
Endogenous reverse transcriptase inhibition and cellular targeting for the prevention and treatment of cancer and aging |
| abstract |
Provided are methods for anti-cancer and anti-aging therapy by administering an inhibitor of reverse transcriptase (RT) activity that functions to inhibit RT encoded by ORF2 of LINE1 or that may be involved in reverse transcription elements Any RT that is transcriptionally activated. Methods are provided to discover new compounds that inhibit RT. The methods are applicable to populations of cancer cells, precancerous cells and somatic cells. Provided are methods for monitoring the efficacy of treatments that inhibit the development of resistance to agents, methods for preventing and/or treating pathologies associated with the accumulation of somatic cells capable of spontaneously generating genetic inheritance independent of cell division Variety. Methods are provided for the treatment and/or prevention of age-related conditions in an individual by administering an agent capable of selectively killing cells exhibiting genetic instability. Methods are provided for sensitizing cancer cells to chemotherapeutic agents by administering RT inhibitors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114657281-A |
| priorityDate |
2017-01-23^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |